Sandoz a unit of biopharmaceutical major Novartis AG (NVS) said on Monday that it has completed acquiring the worldwide brand rights of the antifungal agent Mycamine from Astellas Pharma Inc. (ALPMY), a Japanese pharmaceutical company.
With this acquisition Sandoz hopes to reinforces its global hospital offering and leading anti-infectives portfolio.
For the year ending March 2023, Astellas had reported Mycamine sales worth $105 million. The antifungal agent has a patient base over two million.
According to the company, it is a therapy of choice in hospitals and intensive care units worldwide. It is a proven prophylactic in hematology and oncology patients and is widely used in organ transplants. It is also used for the treatment of invasive candidiasis and esophageal candidiasis and is a preventive treatment for candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
On Friday, shares of Novartis closed at $101.78 up 0.93% on the New York Stock exchange and shares of Astellas closed at 2200 yen up 0.94% on the Tokyo Stock Exchange today.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.